ClinicalTrials.gov
public full text
Public Domain
Sapu003 in Advanced mTOR-sensitive Solid Tumors
This is a phase 1b, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics of Sapu003 in combination with Exemestane in in patients with advanced mTOR-sensitive solid tumors (HR+/HER2-negative breast cancer, renal cell carcinoma \[RCC\], neuroendocrine tumors \[NETs\], tuberous sclerosis complex \[TSC\]-associated tumors, and hepatocellular carcinoma \[HCC\]).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Insulin Titration System Based on Deep Learning#1455055
- Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial#1455056
- Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy#1455057
- PO vs IV Antibiotics for the Treatment of Infected Nonunion of Fractures After Fixation#1455059
- Multimodal Intervention for Weight Management and Health in the Elderly Population#1455061
Record · ID 1454130
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive